Simcere Showcases Promising Bladder Cancer Data for Novel Immunotherapy SIM0237

Simcere Pharmaceutical Group Limited ( (HK:2096) ) has shared an update.

Simcere Pharmaceutical Group Limited has reported new Phase I/II clinical data for SIM0237, a PD-L1/IL15v bispecific fusion protein it independently developed, in patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer. Presented at the European Association of Urology Annual Congress 2026, the results highlight SIM0237’s dual mechanism of blocking the PD-1/PD-L1 pathway while activating IL-15-mediated immune responses.

As of late November 2025, 49 patients had received intravesical SIM0237 monotherapy, with 80% of carcinoma in situ patients achieving complete response and a 12-month disease-free survival rate of 65.8% in papillary-only cases, indicating promising efficacy in a difficult-to-treat population. Safety data showed favorable tolerability and no detectable systemic exposure after intravesical administration, suggesting potential for a localized, lower-risk immunotherapy option that could strengthen Simcere’s position in oncology and bladder cancer therapeutics.

The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.

More about Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited is an innovation-driven pharmaceutical company focused on neuroscience, oncology, autoimmune and anti-infection therapies, supported by its State Key Laboratory of Neurology and Oncology Drug Development. Leveraging proprietary protein engineering technology and in-house R&D, it collaborates with innovative companies and research institutes to address significant current and future clinical needs.

Average Trading Volume: 6,528,812

Technical Sentiment Signal: Buy

Current Market Cap: HK$31.3B

See more data about 2096 stock on TipRanks’ Stock Analysis page.